ArticleFrontiers in oncology2025
MRI-based radiomics nomogram for predicting CD8-positive tumor-infiltrating lymphocytes levels in HER2-positive breast cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PET/CT imaging for assessment of tumor immunotherapy response: a new perspective on tumor metabolic reprogramming and immune escape.La Radiologia medica · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop a radiomics nomogram based on radiomic features derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) combined with clinical-imaging characteristics in predicting the CD8+Tumor-infiltrating lymphocytes (TILs) levels in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). Materials and methods: A total of 126 BC patients with pathologically confirmed HER2-positive were enrolled and randomly divided into training (n = 88) and validation (n = 38) cohorts. A clinical-imaging model was built based on clinical and MRI characteristics. Radiomics features were extracted from the third post-contrast phase on DCE-MRI. Select K Best, the maximum relevance minimum redundancy (mRMR), and least absolute shrinkage and selection operator algorithm (LASSO) were used to select radiomics features and a radiomics signature score (rad-score) was constructed by seven radiomics features. Multivariate logistic regression analysis was used to construct a radiomics nomogram model by combining with rad-score and independent clinical-imaging factors. Performance of the clinical-imaging model, rad-score, and radiomics nomogram model were evaluated using the area under the curve (AUC). Results: Seven radiomics features were used to build the rad-score. The rad-score achieved good performance in predicting CD8+TILs with AUCs= 0.853 and 0.822, respectively. The radiomics nomogram model based on rad-score and clinical-imaging features (tumor margin and enhancement pattern) yielded an optimal AUC of 0.866 and 0.886 in the training and validation cohorts, respectively. The radiomics nomogram significantly outperformed the clinical-imaging model (p < 0.05) and showed a trend toward better performance compared to the rad-score alone (p > 0.05). Conclusions: The MRI-based radiomics nomogram has the ability to predict CD8+TILs levels, which could be useful in identifying potential in HER2-positive BC patients who can benefit from immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.